Your browser doesn't support javascript.
Hydroxychloroquine for Early Treatment of Adults With Mild Coronavirus Disease 2019: A Randomized, Controlled Trial.
Mitjà, Oriol; Corbacho-Monné, Marc; Ubals, Maria; Tebé, Cristian; Peñafiel, Judith; Tobias, Aurelio; Ballana, Ester; Alemany, Andrea; Riera-Martí, Núria; Pérez, Carla A; Suñer, Clara; Laporte, Pep; Admella, Pol; Mitjà, Jordi; Clua, Mireia; Bertran, Laia; Sarquella, Maria; Gavilán, Sergi; Ara, Jordi; Argimon, Josep M; Casabona, Jordi; Cuatrecasas, Gabriel; Cañadas, Paz; Elizalde-Torrent, Aleix; Fabregat, Robert; Farré, Magí; Forcada, Anna; Flores-Mateo, Gemma; Muntada, Esteve; Nadal, Núria; Narejos, Silvia; Nieto, Aroa; Prat, Nuria; Puig, Jordi; Quiñones, Carles; Reyes-Ureña, Juliana; Ramírez-Viaplana, Ferran; Ruiz, Lidia; Riveira-Muñoz, Eva; Sierra, Alba; Velasco, César; Vivanco-Hidalgo, Rosa Maria; Sentís, Alexis; G-Beiras, Camila; Clotet, Bonaventura; Vall-Mayans, Martí.
  • Mitjà O; Fight AIDS and Infectious Diseases Foundation, Badalona, Spain.
  • Corbacho-Monné M; Hospital Universitari Germans Trias i Pujol and Universitat Autònoma de Barcelona, Badalona, Spain.
  • Ubals M; Lihir Medical Centre-International SOS, Lihir Island, Papua New Guinea.
  • Tebé C; Fight AIDS and Infectious Diseases Foundation, Badalona, Spain.
  • Peñafiel J; Facultat de Medicina, Universitat de Barcelona, Barcelona, Spain.
  • Tobias A; Hospital Universitari Germans Trias i Pujol and Universitat Autònoma de Barcelona, Badalona, Spain.
  • Ballana E; Facultat de Medicina, Universitat de Barcelona, Barcelona, Spain.
  • Alemany A; Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Spain.
  • Riera-Martí N; Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Spain.
  • Pérez CA; Institute of Environmental Assessment and Water Research (IDAEA), Spanish Council for Scientific Research (CSIC), Barcelona, Spain.
  • Suñer C; IrsiCaixa AIDS Research Institute, Germans Trias i Pujol Research Institute (IGTP), Badalona, Spain.
  • Laporte P; Fight AIDS and Infectious Diseases Foundation, Badalona, Spain.
  • Admella P; Fight AIDS and Infectious Diseases Foundation, Badalona, Spain.
  • Mitjà J; Fight AIDS and Infectious Diseases Foundation, Badalona, Spain.
  • Clua M; Fight AIDS and Infectious Diseases Foundation, Badalona, Spain.
  • Bertran L; Fight AIDS and Infectious Diseases Foundation, Badalona, Spain.
  • Sarquella M; Fight AIDS and Infectious Diseases Foundation, Badalona, Spain.
  • Gavilán S; Fight AIDS and Infectious Diseases Foundation, Badalona, Spain.
  • Ara J; Fight AIDS and Infectious Diseases Foundation, Badalona, Spain.
  • Argimon JM; Fight AIDS and Infectious Diseases Foundation, Badalona, Spain.
  • Casabona J; Fight AIDS and Infectious Diseases Foundation, Badalona, Spain.
  • Cuatrecasas G; Fight AIDS and Infectious Diseases Foundation, Badalona, Spain.
  • Cañadas P; Hospital Universitari Germans Trias i Pujol and Universitat Autònoma de Barcelona, Badalona, Spain.
  • Elizalde-Torrent A; Direcció-gerència, Institut Català de la Salut, Barcelona, Spain.
  • Fabregat R; Centre of Epidemiological Studies of HIV/AIDS and STI of Catalonia (CEEISCAT), Catalan Institute of Oncology (ICO)-Departament de Salut, Generalitat de Catalunya, Barcelona, Spain.
  • Farré M; Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.
  • Forcada A; Equip d'atenció primària de Sarria, Barcelona, Spain.
  • Flores-Mateo G; SYNLAB, Barcelona, Spain.
  • Muntada E; IrsiCaixa AIDS Research Institute, Germans Trias i Pujol Research Institute (IGTP), Badalona, Spain.
  • Nadal N; Direcció General de Recerca i Innovació en Salut, Generalitat de Catalunya, Barcelona, Catalonia, Spain.
  • Narejos S; Hospital Universitari Germans Trias i Pujol and Universitat Autònoma de Barcelona, Badalona, Spain.
  • Nieto A; Gerència territorial de Catalunya Central, Institut Català de la Salut, St Fruitós del Bages, Spain.
  • Prat N; Xarxa Sanitària i Social Santa Tecla, Tarragona, Spain.
  • Puig J; Centre of Epidemiological Studies of HIV/AIDS and STI of Catalonia (CEEISCAT), Catalan Institute of Oncology (ICO)-Departament de Salut, Generalitat de Catalunya, Barcelona, Spain.
  • Quiñones C; Gerència territorial de Barcelona, Institut Català de la Salut, Barcelona, Spain.
  • Reyes-Ureña J; Entitat de Base Asociativa Centelles- Atenció Primària, Centelles, Spain.
  • Ramírez-Viaplana F; Fight AIDS and Infectious Diseases Foundation, Badalona, Spain.
  • Ruiz L; Gerència territorial de Àmbit Metropolità nord, Institut Català de la Salut, Sabadell, Spain.
  • Riveira-Muñoz E; Fight AIDS and Infectious Diseases Foundation, Badalona, Spain.
  • Sierra A; Hospital Universitari Germans Trias i Pujol and Universitat Autònoma de Barcelona, Badalona, Spain.
  • Velasco C; Centre of Epidemiological Studies of HIV/AIDS and STI of Catalonia (CEEISCAT), Catalan Institute of Oncology (ICO)-Departament de Salut, Generalitat de Catalunya, Barcelona, Spain.
  • Vivanco-Hidalgo RM; Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.
  • Sentís A; Fight AIDS and Infectious Diseases Foundation, Badalona, Spain.
  • G-Beiras C; IrsiCaixa AIDS Research Institute, Germans Trias i Pujol Research Institute (IGTP), Badalona, Spain.
  • Clotet B; IrsiCaixa AIDS Research Institute, Germans Trias i Pujol Research Institute (IGTP), Badalona, Spain.
  • Vall-Mayans M; Fight AIDS and Infectious Diseases Foundation, Badalona, Spain.
Clin Infect Dis ; 73(11): e4073-e4081, 2021 12 06.
Article in English | MEDLINE | ID: covidwho-1560481
ABSTRACT

BACKGROUND:

No effective treatments for coronavirus disease 2019 (COVID-19) exist. We aimed to determine whether early treatment with hydroxychloroquine (HCQ) would be efficacious for outpatients with COVID-19.

METHODS:

Multicenter open-label, randomized, controlled trial conducted in Catalonia, Spain, between 17 March and 26 May 2020. Patients recently diagnosed with <5-day of symptom onset were assigned to receive HCQ (800 mg on day 1 followed by 400 mg once daily for 6 days) or usual care. Outcomes were reduction of viral load in nasopharyngeal swabs up to 7 days after treatment start, disease progression up to 28 days, and time to complete resolution of symptoms. Adverse events were assessed up to 28 days.

RESULTS:

A total of 293 patients were eligible for intention-to-treat

analysis:

157 in the control arm and 136 in the intervention arm. The mean age was 41.6 years (SD, 12.6), mean viral load at baseline was 7.90 log10 copies/mL (SD, 1.82), and median time from symptom onset to randomization was 3 days. No differences were found in the mean reduction of viral load at day 3 (-1.41 vs -1.41 log10 copies/mL in the control and intervention arm, respectively) or at day 7 (-3.37 vs -3.44). Treatment did not reduce risk of hospitalization (7.1% control vs 5.9% intervention) nor shorten the time to complete resolution of symptoms (12 days, control vs 10 days, intervention). No relevant adverse events were reported.

CONCLUSIONS:

In patients with mild COVID-19, no benefit was observed with HCQ beyond the usual care.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Drug Treatment / Hydroxychloroquine Type of study: Experimental Studies / Prognostic study / Randomized controlled trials Limits: Adult / Humans Language: English Journal: Clin Infect Dis Journal subject: Communicable Diseases Year: 2021 Document Type: Article Affiliation country: Cid

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Drug Treatment / Hydroxychloroquine Type of study: Experimental Studies / Prognostic study / Randomized controlled trials Limits: Adult / Humans Language: English Journal: Clin Infect Dis Journal subject: Communicable Diseases Year: 2021 Document Type: Article Affiliation country: Cid